EP0705433A4 - Zusammensetzungen und verfahren zum testen auf nicht anhängigmachende narkotische analgetische wirkung und beleuchtungen - Google Patents

Zusammensetzungen und verfahren zum testen auf nicht anhängigmachende narkotische analgetische wirkung und beleuchtungen

Info

Publication number
EP0705433A4
EP0705433A4 EP94920259A EP94920259A EP0705433A4 EP 0705433 A4 EP0705433 A4 EP 0705433A4 EP 94920259 A EP94920259 A EP 94920259A EP 94920259 A EP94920259 A EP 94920259A EP 0705433 A4 EP0705433 A4 EP 0705433A4
Authority
EP
European Patent Office
Prior art keywords
addicting
treatments
compositions
methods
analgesic activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94920259A
Other languages
English (en)
French (fr)
Other versions
EP0705433A1 (de
Inventor
Wolfgang Sadee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of EP0705433A1 publication Critical patent/EP0705433A1/de
Publication of EP0705433A4 publication Critical patent/EP0705433A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486Analgesics, e.g. opiates, aspirine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
EP94920259A 1993-06-23 1994-06-17 Zusammensetzungen und verfahren zum testen auf nicht anhängigmachende narkotische analgetische wirkung und beleuchtungen Withdrawn EP0705433A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81612 1979-10-03
US8161293A 1993-06-23 1993-06-23
US26150094A 1994-06-16 1994-06-16
US261500 1994-06-16
PCT/US1994/006883 WO1995000848A1 (en) 1993-06-23 1994-06-17 Compositions and methods for anti-addictive narcotic analgesis acivity screening and treatments

Publications (2)

Publication Number Publication Date
EP0705433A1 EP0705433A1 (de) 1996-04-10
EP0705433A4 true EP0705433A4 (de) 2001-09-26

Family

ID=26765751

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94920259A Withdrawn EP0705433A4 (de) 1993-06-23 1994-06-17 Zusammensetzungen und verfahren zum testen auf nicht anhängigmachende narkotische analgetische wirkung und beleuchtungen

Country Status (5)

Country Link
EP (1) EP0705433A4 (de)
JP (1) JPH08512129A (de)
AU (1) AU7112094A (de)
CA (1) CA2164966A1 (de)
WO (1) WO1995000848A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882944A (en) * 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
JP4442930B2 (ja) 1995-12-11 2010-03-31 タフツ メディカル センター インコーポレイテッド ペプチドホルモンレセプターリガンドに関するアッセイ法およびその使用
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
CN1420929A (zh) 2000-04-07 2003-05-28 阿瑞那制药公司 非内源性组成型活化的已知g蛋白偶联受体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061715A (en) * 1989-11-13 1991-10-29 Merrell Dow Pharmaceuticals Inc. Prevention of glycoprotein enveloped virus infectivity by quinolyl- and isoquinolyloxazole-2-zones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COSTA E.M. ET AL: "Opioid agonists binding and responses in SH-SY5Y cells", LIFE SCIENCES, vol. 50, 1991, pages 73 - 81, XP001008484 *

Also Published As

Publication number Publication date
CA2164966A1 (en) 1995-01-05
EP0705433A1 (de) 1996-04-10
AU7112094A (en) 1995-01-17
WO1995000848A1 (en) 1995-01-05
JPH08512129A (ja) 1996-12-17

Similar Documents

Publication Publication Date Title
BR9609132A (pt) Composicão e método de tratamento de semente
EP1027045A4 (de) Methoden und zusammenstellungen zur regelierung des s-alpha-reduktaseaktivität
DE69614211D1 (de) Gerät zur Erfassung und Anzeige von zusätzlichen Programmen
FI942744A7 (fi) Metalloseeneja ja siihen liittyviä menetelmiä
EP0659211A4 (de) Verfahren und therapeutische zusammensetzungen zur behandlung von zystischer fibrose.
DE69616179D1 (de) Verriegelbarer Nadelspitzenschutz
DE69623877D1 (de) Verriegelbarer Nadelspitzenschutz
IT1283443B1 (it) Dispositivo e metodo per rinforzare punti chirurgici
NO973836D0 (no) Benzopyran-inneholdende forbindelser og fremgangsmåte for anvendelse derav
BR9612263A (pt) Compostos quinolina e qinazolina úteis em terapia
FR2650964B1 (fr) Catalyseur d'hydrogenation a base de compose du titane et procede d'hydrogenation l'utilisant
EP1042540A4 (de) Programmiertes pulselektrobeschichtungsverfahren
DE69419033D1 (de) Paroxetin enthaltende tabletten und verfahren
BR9306128A (pt) Barra proveniente de freezer de ph da pele e processo
BR9607347A (pt) Esteres e amidas de 1,4-piperidina dissubstítuída possuindo atividade antagonística 5-ht
FI972865L (fi) Hydroksimetyyli-imidatsodiatseptiinejä ja niiden esterit
FI960930A7 (fi) Menetelmiä erytropoieesin stimuloimiseksi trombopoietiinia käyttämällä
FI954499L (fi) Menetelmä ja analyysi
ITTO950580A0 (it) Cursore bloccabile per chiusure lampo
FI960912A7 (fi) Massan valmistus- ja varastointimenetelmä ja laite
DE69407483D1 (de) Aufzeichnungsgerät und Aufzeichnungsverfahren
EP0705433A4 (de) Zusammensetzungen und verfahren zum testen auf nicht anhängigmachende narkotische analgetische wirkung und beleuchtungen
KR940021607U (ko) 관상어용장치 및 그 콘센트
FI960301L (fi) Nikkelitön hemoglobiini ja menetelmät sellaisen hemoglobiinin tuottamiseksi
DE69425770D1 (de) Direktes Aufzeichnungsverfahren und direkte Aufzeichnungsvorrichtung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: G01N 33/554

A4 Supplementary search report drawn up and despatched

Effective date: 20010810

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/00 A, 7G 01N 33/50 B, 7G 01N 33/94 B, 7C 07K 14/705 B, 7A 61K 31/47 B

17Q First examination report despatched

Effective date: 20020131

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020611